PTPN3

Across TCGA pan-cancer cohorts, PTPN3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTPN3 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PTPN3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PTPN3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where PTPN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.805	0.521	<.001	30	view →
LUAD	OS	Median	II,III,IV	1.000	0.862	.004	18	view →
LSCC	DFS	Median	III,IV	0.910	0.449	.003	12	view →
CCRCC	DFS	Median	II,III,IV	1.000	0.355	.012	10	view →
UCEC	OS	Tertile	All	1.000	0.834	.011	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTPN3–HNSC (DFS)

Open the HNSC breakdown →